

TEVA PHARMACEUTICAL INDUSTRIES LTD  
Form SD  
May 31, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM SD**

**SPECIALIZED DISCLOSURE REPORT**

**TEVA PHARMACEUTICAL INDUSTRIES LIMITED**

**(Exact name of the registrant as specified in its charter)**

**ISRAEL**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**001-16174**  
**(Commission**  
**File Number)**

**N/A**  
**(IRS Employer**  
**Identification No.)**

**5 Basel Street, P.O. Box 3190, Petach Tikva, Israel**  
**(Address of principal executive offices)**

**4951033**  
**(Zip code)**

**Michael McClellan**

**Executive Vice President, Chief Financial Officer**

**Tel: 972-3-926-7267**

**(Name and telephone number, including area code, of the person to contact in connection with this report.)**

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017.

**Items 1.01 and 1.02 Conflict Minerals Disclosure, Exhibit**

***Conflict Minerals Disclosure and Report***

A copy of the Company's Conflict Minerals Report is provided as Exhibit 1.01 hereto and is publicly available at [http://www.tevapharm.com/files/about/corporate\\_governance/governance\\_doc/TEVA PHARMACEUTICAL INDUSTRIES](http://www.tevapharm.com/files/about/corporate_governance/governance_doc/TEVA_PHARMACEUTICAL_INDUSTRIES)

**Item 2.01 Exhibits**

Listed below is the following exhibit filed as part of this report:

Exhibit 1.01 Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED  
(Registrant)

/s/ **Michael McClellan**

By **Michael McClellan**  
Executive Vice President, Chief  
Financial Officer

May 31, 2018